Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

Orgenesis logo
$2.01 0.00 (0.00%)
As of 05/21/2025

About Orgenesis Stock (NASDAQ:ORGS)

Key Stats

Today's Range
$2.01
$2.01
50-Day Range
$1.77
$3.49
52-Week Range
$0.87
$10.80
Volume
2 shs
Average Volume
9,768 shs
Market Capitalization
$9.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Stock News Headlines

Orgenesis Delays Filing of Quarterly Report
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
See More Headlines

ORGS Stock Analysis - Frequently Asked Questions

Orgenesis' stock was trading at $1.89 at the beginning of 2025. Since then, ORGS stock has increased by 6.3% and is now trading at $2.01.
View the best growth stocks for 2025 here
.

Orgenesis Inc. (NASDAQ:ORGS) issued its quarterly earnings data on Friday, August, 11th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The business had revenue of $6.98 million for the quarter.

Shares of Orgenesis reverse split before market open on Wednesday, September 25th 2024. The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orgenesis subsidiaries include Koligo Therapeutics, and Tamir Biotechnology Inc.

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

Last Earnings
8/11/2023
Today
5/22/2025
Next Earnings (Estimated)
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
150
Year Founded
2008

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,360,000.00
Net Margins
-3,827.81%
Pretax Margin
-3,931.93%

Debt

Sales & Book Value

Annual Sales
$662,000.00
Price / Cash Flow
N/A
Book Value
($6.58) per share
Price / Book
-0.31

Miscellaneous

Free Float
4,527,000
Market Cap
$9.65 million
Optionable
No Data
Beta
0.72

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ORGS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners